Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib

Leukemia Research

Volumn 37, Issue 5, 2013, Pages 487-495

  Quintás Cardama, Alfonso ^a   Jabbour, Elias J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Adverse drug event; Chronic myeloid leukemia; Dasatinib; Drug resistance; Imatinib; Nilotinib

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB;

ANEMIA; ARTHRALGIA; BONE PAIN; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EARLY INTERVENTION; EVENT FREE SURVIVAL; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINE RETENTION;

BENZAMIDES; DRUG SUBSTITUTION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 84875880394     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.01.006     Document Type: Review

References (58)

1. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
2. Deininger M., O'Brien S.G., Guilhot F., Goldman J.M., Hochhaus A., Hughes T.P., et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annu Meet Abstr) 2009, 114:1126.
3. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
4. Hochhaus A., O'Brien S.G., Guilhot F., Druker B.J., Branford S., Foroni L., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
5. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myelogenous Leukemia V.3.2013. © National Comprehensive Cancer Network, Inc. 2013. All rights reserved. Accessed January 9, 2013. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
7. O'Brien S., Berman E., Moore J.O., Pinilla-Ibarz J., Radich J.P., Shami P.J., et al. NCCN task force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw 2011, 9(Suppl. 2):S1-S25.
8. Iclusig (Ponatinib) [Prescribing Information]. Cambridge, MA: ARIAD Pharmaceuticals, Inc., 2012.
9. Kantarjian H., O'Brien S., Garcia-Manero G., Faderl S., Ravandi F., Jabbour E., et al. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer 2012, Feb 27 [Epub ahead of print].
10. Hughes T.P., Hochhaus A., Branford S., Muller M.C., Kaeda J.S., Foroni L., et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010, 116:3758-3765.
11. Quintas-Cardama A., Kantarjian H., Jones D., Shan J., Borthakur G., Thomas D., et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009, 113:6315-6321.
12. Marin D., Milojkovic D., Olavarria E., Khorashad J.S., de Lavallade H., Reid A.G., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008, 112:4437-4444.
13. Kim D., Goh H.G., Kim S.H., Choi S.Y., Park S.H., Jang E.J., et al. Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. Int J Hematol 2012, May 19 [Epub ahead of print].
14. Branford S., Rudzki Z., Harper A., Grigg A., Taylor K., Durrant S., et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003, 17:2401-2409.
15. Yeung D.T., Osborn M., White D.L., Branford S., Kornhauser M., Slader C., et al. Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk of progression - an update of the TIDEL-II trial. Blood (ASH Annu Meet Abstr) 2011, 118:451.
16. Naqvi K., Kantarjian H.M., Luthra R., Jabbour E., O'Brien S., Burton E.M., et al. Kinetics of molecular response with different tyrosine kinase inhibitors (TKI) used as frontline therapy in chronic myeloid leukemia-chronic phase (CML CP). Blood (ASH Annu Meet Abstr) 2011, 118:3784.
17. Hanfstein B., Muller M.C., Erben P., Lauseker M., Saussele S., Proetel U., et al. Molecular and cytogenetic response after 3 months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients - a follow-up analysis of the German CML Study IV. Blood (ASH Annu Meet Abstr) 2011, 118:783.
18. Marin D., Ibrahim A.R., Lucas C., Gerrard G., Wang L., Szydlo R.M., et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012, 30:232-238.
19. Alvarado Y., Kantarjian H., O'Brien S., Faderl S., Borthakur G., Burger J., et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009, 115:3709-3718.
20. Castagnetti F., Gugliotta G., Palandri F., Breccia M., Amabile M., Iacobucci I., et al. Chronic myeloid leukemia (CML) patients with suboptimal "response to imatinib (IM) according to European LeukemiaNet criteria have a poorer outcome with respect to optimal" responders: a GIMEMA CML working party analysis. ASH Annu Meet Abstr 2009, 114:2196.
21. Hochhaus A., Boqué C., Bradley Garelik M., Manos G., Steegmann J.L. Molecular response kinetics and BCR-ABL reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib vs imatinib: DASISION 3-year follow-up. Haematologica 2012, 97(s1):76. (abstract 0192).
22. Hochhaus A., Guilhot F., Kathrin Haifa A.A., Rosti G., Nakaseko C., De Souza C.A., et al. Early BCR-ABL transcript levels predict future molecular response and long-term outcomes in newly diagnosed patients with chronic myeloid leukemia in chronic phase: analysis of ENESTnd 3-year data. Haematologica 2012, 97(s1):237. (abstract 0584).
23. Jabbour E., Kantarjian H., O'Brien S., Shan J., Quintas-Cardama A., Faderl S., et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011, 118:4541-4546. quiz 759.
24. Marin D., Hedgley C., Clark R.E., Apperley J., Foroni L., Milojkovic D., et al. The predictive value of early molecular response in chronic phase CML patients treated with dasatinib first line therapy. Blood (ASH Annu Meet Abstr) 2011, 118:785.
25. Nicolini F.E., Hayette S., Labussiere H., Etienne M., Fort M.P., Gadolet E., et al. The month three major molecular response in chronic phase chronic myeloid leukemia on imatinib 400, nilotinib and dasatinib is a major prognostic factor for failure-free and progression-free survival. Blood (ASH Annu Meet Abstr) 2011, 118:1684.
26. White D.L., Hughes T.P. Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. J Clin Oncol 2012, 30:1144-1145.
27. Marin D., Bazeos A., Mahon F.X., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28:2381-2388.
28. Noens L., van Lierde M.A., De Bock R., Verhoef G., Zachee P., Berneman Z., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
29. Tasigna (Nilotinib) [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2011.
30. Sprycel (Dasatinib) [Prescribing Information]. Princeton, NJ: Bristol-Myers Squibb, 2011.
31. Bosulif (Bosutinib) [Prescribing Information]. New York, NY: Pfizer Labs, 2012.
32. Garcia-Gutierrez J.V., Herrera P., Abalo L.L., Rey M.D., Calbacho M., Ramos L., et al. Impact of second-generation tyrosine kinase inhibitors as second line treatment for patients with chronic myeloid leukemia. Blood (ASH Annu Meet Abstr) 2011, 118:3780.
33. Goh H.G., Jootar S., Kim H.J., Sohn S.K., Park J.S., Kim S.H., et al. Efficacy of nilotinib versus high-dose imatinib in early chronic phase CML patients who have suboptimal molecular responses to standard-dose imatinib (RE-NICE multicenter study). Blood (ASH Annu Meet Abstr) 2011, 118:2765.
34. Kantarjian H., Pasquini R., Hamerschlak N., Rousselot P., Holowiecki J., Jootar S., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007, 109:5143-5150.
35. Kantarjian H., Pasquini R., Levy V., Jootar S., Holowiecki J., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009, 115:4136-4147.
36. Yeung D.T., Osborn M.P., Branford S., Slader C., Hiwase D.K., Schwarer A.P., et al. Early switch to nilotinib does not overcome the adverse outcome for CML patients failing to achieve early molecular response on imatinib, despite excellent overall outcomes in the TIDEL II trial. Blood (ASH Annu Meet Abstr) 2012, 120:3771.
37. Quintas-Cardama A., Cortes J.E., O'Brien S., Ravandi F., Borthakur G., Liu D., et al. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009, 115:2912-2921.
38. Branford S., Lawrence R., Fletcher L., Field C., Rudzki Z., Hughes T. The initial molecular response of chronic phase CML patients treated with second generation ABL inhibitor therapy after imatinib failure can predict inadequate response and provide indications for rational mutation screening. Blood (ASH Annu Meet Abstr) 2008, 112:331.
39. Gleevec (Imatinib) [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2011.
40. Cortes J.E., Hochhaus A., le Coutre P.D., Rosti G., Pinilla-Ibarz J., Jabbour E., et al. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 2011, 117:5600-5606.
41. Khoury H.J., Goldberg S.L., Mauro M.J., Stone R.M., Matloub Y., Chen T., et al. Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety. J Clin Oncol 2008, 26(Suppl.):7015.
42. Cortes J.E., Kantarjian H.M., Brummendorf T.H., Kim D.W., Turkina A.G., Shen Z.X., et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib. Blood 2011, 118:4567-4576.
43. Fogarty M. How cancer treatment benefits from the industry's input. Oncol Times 2008, 5:3.
44. Kantarjian H.M., Cortes J., Guilhot F., Hochhaus A., Baccarani M., Lokey L. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer 2007, 109:1365-1375.
45. Quintas-Cardama A., Flamm M., Lill M., Bollu V., Guo A., Niyazov A., et al. Resource utilization and perceptions of major molecular response in chronic myeloid leukemia (CML): results of a Delphi panel study. Presented at International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting 2011.
46. Larson R.A., Druker B.J., Guilhot F., O'Brien S.G., Riviere G.J., Krahnke T., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022-4028.
47. Faderl S., Talpaz M., Estrov Z., Kantarjian H.M. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999, 131:207-219.
48. Ohm L., Arvidsson I., Barbany G., Hast R., Stenke L. Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome. Am J Hematol 2012, 87:760-765.
49. Latagliata R., Breccia M., Carmosino I., Vozella F., Volpicelli P., Ferretti A., et al. Complete cytogenetic response after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia. Blood (ASH Annu Meet Abstr) 2011, 118:3783.
50. Hochhaus A., Saglio G., Chuah C., Pavlovsky C., Garelick M.B.B., Lambert A., et al. Dasatinib and imatinib-induced reductions in BCR-ABL transcript levels below 10% at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of molecular response kinetics in the DASISION trial. Blood (ASH Annu Meet Abstr) 2011, 118:2767.
51. Kantarjian H.M., Giles F.J., Bhalla K.N., Pinilla-Ibarz J., Larson R.A., Gattermann N., et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011, 117:1141-1145.
52. Le Coutre P., Giles F.J., Pinilla-Ibarz J., Larson R., Gattermann N., Ottmann O.G., et al. Nilotinib in imatinib-resistant or -intolerant patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 48-month follow-up results of a phase 2 study. Blood (ASH Annu Meet Abstr) 2011, 118:3770.
53. Ailawadhi S., Miller C.B., Jillella A.P., Koshy N., Tudor B., Akard L.P., et al. Effect of nilotinib (NIL) on molecular response in chronic myelogenous leukemia - chronic phase (CML-CP) patients (pts) with a suboptimal molecular response to imatinib (IM) - ENABL study update. Blood (ASH Annu Meet Abstr) 2011, 118:2771.
54. Hochhaus A., Ossenkoppele G., Reiffers J., Yao M., Shibayama H., Gattermann N., et al. Results from the ENESTnd extension study: efficacy and safety of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP), treated with nilotinib 400mg twice daily (BID) after suboptimal response (SoR) or treatment failure (TF) to imatinib 400mg once daily (QD) or nilotinib 300mg BID. Blood (ASH Annu Meet Abstr) 2011, 118:114.
55. Hughes T., Lipton J.H., Leber B., Spector N., Cervantes F., Pasquini R., et al. Complete molecular response (CMR) rate with nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) without CMR after 2 years on imatinib: preliminary results from the randomized ENESTcmr trial of nilotinib 400mg twice daily (BID) vs imatinib. Blood (ASH Annu Meet Abstr) 2011, 118:606.
56. Hochhaus A., Kantarjian H.M., Baccarani M., Lipton J.H., Apperley J.F., Druker B.J., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007, 109:2303-2309.
57. Shah N.P., Cortes J.E., Schiffer C.A., Guilhot F., Brummendorf T.H., Chen A.C., et al. Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. J Clin Oncol 2011, 29(Suppl.):6512.
58. Shah N.P., Kantarjian H.M., Kim D.W., Rea D., Dorlhiac-Llacer P.E., Milone J.H., et al. Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008, 26:3204-3212.